AMENDMENT NO. 5 TO Securities Purchase AgreementSecurities Purchase Agreement • January 3rd, 2017 • Cipher Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Amendment No. 5 to Securities Purchase AGREEMENT is entered into as of December 30, 2016 (this “Amendment”), among Cipher Pharmaceuticals INC., an Ontario corporation (the “Issuer”), the Guarantors party hereto, Athyrium Opportunities II Acquisition LP, as a Purchaser, the other Purchasers party hereto (collectively, the “Purchasers”) and Athyrium Opportunities II Acquisition LP, as Collateral Agent.
MEMBERSHIP INTERESTS PURCHASE AGREEMENTMembership Interests Purchase Agreement • April 23rd, 2015 • Cipher Pharmaceuticals Inc • Pharmaceutical preparations • New York
AMENDMENT NO. 4 TO SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 30th, 2016 • Cipher Pharmaceuticals Inc • Pharmaceutical preparations • New York
This AMENDMENT NO. 4 TO SECURITIES PURCHASE AGREEMENT is entered into as of September 29, 2016 (this “Amendment”), among CIPHER PHARMACEUTICALS INC., an Ontario corporation (the “Issuer”), the Guarantors party hereto, ATHYRIUM OPPORTUNITIES II ACQUISITION LP, as a Purchaser, the other Purchasers party hereto (collectively, the “Purchasers”) and ATHYRIUM OPPORTUNITIES II ACQUISITION LP, as Collateral Agent.
SECURITIES PURCHASE AGREEMENT Dated as of April 13, 2015 among CIPHER PHARMACEUTICALS INC. as the Issuer, THE SUBSIDIARIES OF THE ISSUER, as the Guarantors, ATHYRIUM OPPORTUNITIES II ACQUISITION LP as Purchaser THE OTHER PURCHASERS LISTED ON SCHEDULE...Securities Purchase Agreement • April 23rd, 2015 • Cipher Pharmaceuticals Inc • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT is entered into as of April 13, 2015 (this “Agreement”), among CIPHER PHARMACEUTICALS INC., an Ontario corporation (the “Issuer”), the Guarantors (defined herein), ATHYRIUM OPPORTUNITIES II ACQUISITION LP, as a Purchaser, the other Purchasers party hereto (and listed on Schedule I) (collectively, the “Purchasers”) and ATHYRIUM OPPORTUNITIES II ACQUISITION LP, as Collateral Agent.
AMENDMENT NO. 1 TO Securities Purchase AgreementSecurities Purchase Agreement • October 6th, 2015 • Cipher Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Amendment No. 1 to Securities Purchase AGREEMENT is entered into as of September 30, 2015 (this “Amendment”), among Cipher Pharmaceuticals INC., an Ontario corporation (the “Issuer”), the Guarantors party hereto, Athyrium Opportunities II Acquisition LP, as a Purchaser, the other Purchasers party hereto (collectively, the “Purchasers”) and Athyrium Opportunities II Acquisition LP, as Collateral Agent.
AMENDMENT NO. 3 TO Securities Purchase AgreementSecurities Purchase Agreement • April 4th, 2016 • Cipher Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Amendment No. 3 to Securities Purchase AGREEMENT is entered into as of March 31, 2016 (this “Amendment”), among Cipher Pharmaceuticals INC., an Ontario corporation (the “Issuer”), the Guarantors party hereto, Athyrium Opportunities II Acquisition LP, as a Purchaser, the other Purchasers party hereto (collectively, the “Purchasers”) and Athyrium Opportunities II Acquisition LP, as Collateral Agent.
AMENDMENT NO. 2 TO Securities Purchase AgreementSecurities Purchase Agreement • January 4th, 2016 • Cipher Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Amendment No. 2 to Securities Purchase AGREEMENT is entered into as of December 29, 2015 (this “Amendment”), among Cipher Pharmaceuticals INC., an Ontario corporation (the “Issuer”), the Guarantors party hereto, Athyrium Opportunities II Acquisition LP, as a Purchaser, the other Purchasers party hereto (collectively, the “Purchasers”) and Athyrium Opportunities II Acquisition LP, as Collateral Agent.
SETTLEMENT AGREEMENTLicense Agreement • October 14th, 2015 • Cipher Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
This Settlement Agreement (including Exhibits A through C, the “Agreement”) is made and entered into this 2nd day of October, 2015 (the “Effective Date”), by and between, on the one hand, Cipher Pharmaceuticals Inc., Galephar Pharmaceutical Research, Inc., Ranbaxy Inc., and Ranbaxy Pharmaceuticals, Inc. (collectively, “Plaintiffs”), and on the other hand, Actavis Laboratories Fl, Inc., Andrx Corp., Actavis, Inc. and Actavis Pharma, Inc. (collectively, “Actavis”) (collectively, the “Parties,” or each separately, a “Party”).
